CORDANT HEALTH SOLUTIONS AND SPERO HEALTH INCREASE NALOXONE ACCESS, SAVE LIVES

PIKEVILLE, Ky., Dec. 15, 2020 -- Cordant Health Solutions®, a leader in providing innovative tools for patients in addiction treatment programs, and Spero Health, an integrated health services organization specializing in the treatment of patients with opioid use disorder, today announced promising results in a new initiative to increase patient awareness of access to naloxone.

Over the last eight months, Cordant has worked with Spero to provide convenient access to medication-assisted treatment (MAT) prescriptions across clinics in Kentucky and Tennessee, including prescriptions for the lifesaving overdose-reversal drug naloxone. 

Rising regional fentanyl use has alarmed addiction specialists, including Dr. Byron Crider, a provider at Spero’s largest clinic in Kentucky. "The Pikeville area saw four overdose deaths in four days. Now more than ever is the time to educate patients and get naloxone to them in a proactive way to help keep them safe," he said. 

At Spero Health, clinicians have candid and open conversations with patients about recovery and risk prevention. The patients then receive delivery of their prescribed naloxone while still at the clinic through Cordant’s managed pharmacy program. During the summer, 486 of Cordant’s MAT pharmacy patients at two of Spero’s treatment clinics in eastern Kentucky received naloxone at their addiction treatment appointment. 

"Four of my patients have already used their initial prescription on a friend or loved one, so I regularly check to see who needs refills," said Crider. "Just as we keep a fire extinguisher in our homes should the unthinkable occur, MAT patients should carry naloxone to protect themselves and their loved ones. Many of my patients have told me they would have never thought about having naloxone in their home, but they are thankful they did." 

"Many providers don’t focus on naloxone as part of addiction treatment, yet research shows that access to naloxone decreases overdose deaths," said Daniel Mandoli, Cordant’s president of pharmacy services. "Delivering naloxone to patients at their office visit through our onsite program ensures they receive it, which is an important step in the process." 

In 2018, almost 47,000 people died of an opioid overdose, and preliminar data from 2019 and 2020 shows this pattern continuing to climb. The U.S. Office of the Surgeon General stated that over 50% of opioid overdose deaths occur in the home and has urged for greater access to naloxone to prevent further deaths. 

####

If you have any questions or would like to interview Dr. Crider please let me know. 
Tiffany Tuetken
Sr. Director of Marketing and Communications
ttuetken@cordanths.com
303-570-4585
About Cordant Health Solutions

Cordant Health Solutions® (cordantsolutions.com) provides innovative tools for monitoring behavioral health, chronic pain and criminal justice cases. Cordant’s unique pharmacy and drug testing programs provide accurate, actionable results to protect prescribers, hold patients accountable and optimize quality of life.

A leader in quality standards, Cordant provides solutions for payers, clinicians and organizations involved with substance use disorder, pain management and criminal justice agencies. Cordant is one of the only healthcare companies that offers monitoring and risk assessment tools through its innovative drug testing options and full-service, high-touch pharmacies, which specialize in the management and dispensing of addiction treatment medications. Cordant’s testing protocols and digital case-management tools help clients become more efficient and effective in using drug testing programs to monitor patient adherence, reduce risk and improve patient outcomes.

About Spero Health

Spero Health, (sperohealth.com) Inc., is an integrated healthcare services organization specializing in local and affordable outpatient care for individuals suffering from substance use disorders with a mission to "Save Lives, Instill Hope, and Restore Relationships." Spero Health utilizes an innovative, evidence-based integrated care model that combines both physical and behavioral healthcare services under one roof to treat the whole patient. This integrated care model combines physician services (including medication-assisted treatment), behavioral health counseling, recovery support services, medication management and patient and family education. Its community-based approach to treatment allows patients to continue working and caring for their families as they overcome addiction.

Based in Nashville, Tenn., and privately held by Heritage Group, Health Velocity Capital, South Central, Inc., and Frist Cressey Ventures, Spero Health operates over 45 outpatient clinics located throughout Kentucky, Indiana, Virginia and Tennessee. Providing care for more than 8,500 patients, Spero is one of the largest office-based opioid treatment providers in the country and is in-network with Medicaid and most commercial insurance plans.

Canadian Vaccine Catalogue releases critical standardized terminology for COVID-19 vaccines

OTTAWA, ON, Dec. 15, 2020 /CNW/ - Standardized vaccine terminology and product information will be critical in the rollout of COVID-19 vaccines to ensure consistency across Canada.

The Canadian Vaccine Catalogue (CVC) is the comprehensive, standards-based resource for vaccine terminology and vaccine product information in the country. CANImmunize, which created the CVC, has updated the resource with the latest COVID-19 vaccine codes and information. 

"It is essential that digital systems tracking COVID-19 vaccinations use the standardized terminology in the Canadian Vaccine Catalogue to ensure people receive the correct vaccine for their second dose, and to help with safety and effectiveness assessments," says Cameron Bell, Chief Technology Officer, CANImmunize. 

This standardized vaccine terminology is essential for governments, electronic medical record vendors and any organization tracking COVID-19 immunization data, as it will permit the timely aggregation and reporting of data across the country for surveillance purposes. 

Features

• Standardized terminology and COVID-19 vaccine product information to allow real-time capture and digital exchange of immunization records across healthcare domains and jurisdictions. 
• Includes vaccine DIN, lot and expiry information directly from Health Canada, Global Trade Item Numbers to support vaccine barcode scanning, and leverages the SNOMED CT Canadian Edition Immunization codes published and maintained by Canada Health Infoway. 

Tradename COVID-19 vaccine codes:

• 28581000087106 – PFIZER-BIONTECH COVID-19 messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for dilution for injection Pfizer Canada ULC-BioNTech Manufacturing GmbH (real clinical drug) 
• 28571000087109 – MODERNA COVID-19 messenger ribonucleic acid-1273 100 micrograms per 0.5 milliliter liquid for injection Moderna Therapeutics Inc. (real clinical drug)

Generic COVID-19 vaccine codes:

• 28531000087107 – Vaccine product against disease caused by Severe acute respiratory syndrome coronavirus 2 (medicinal product) 
• 1119349007 – Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product)

COVID-19 Antigen code:

• 840536004 – Antigen of Severe acute respiratory syndrome coronavirus 2 (substance)

COVID-19 Disease code:

• 840539006 – Disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder)

British Columbia Provincial Health Services Authority and the Ontario Ministry of Health and Long-term Care currently use the CVC to configure their immunization repositories. The CVC also populates the vaccine information in the CANImmunize Clinic Flow product and the public CANImmunize app.

The catalogue is maintained and made available for national use through funding from Canada Health Infoway. 

Explore the Canadian Vaccine Catalogue here. 

ABOUT CANImmunize
CANImmunize is a technology company specializing in immunization software. It developed the CANImmunize platform, a pan-Canadian digital immunization tracking system that helps Canadians keep track of their vaccinations with a mobile app and web portal. The team offers digital solutions to businesses, health care organizations and governments for vaccinations and tracking, and is preparing for the COVID-19 vaccine rollout.

SOURCE CANImmunize

Switch Health Receives Health Canada Authorization for COVID-19 At-Home Collection Kits

• Health Canada authorizes Switch Health's COVID-19 at-home specimen collection kits. 
• At-home specimen collection kits will soon be available online and in participating pharmacy retailers. 
• Switch Health launches proprietary videoconferencing software, ASMO, for step-by-step instructional support for guided collection at-home. ASMO connects directly to partner laboratories for fast and secure results.
• The company continues to work with provinces to bring COVID-19 at-home collection kits to market.

TORONTO, Dec. 15, 2020 /CNW/ - Switch Health, a Canadian healthcare company and industry leader in testing solutions, is pleased to announce Health Canada authorization for the company's COVID-19 at-home specimen collection kits.

The collection kits will provide Canadians with accessible and reliable testing nationwide. At-home collection kits are best suited for asymptomatic individuals who require testing for work, travel or desire regular screening. The kits are enabled via Switch Health's proprietary PHIPA-compliant videoconferencing software, ASMO, where patients are provided step-by-step instructions for proper self-collection.

Switch Health's COVID-19 at-home specimen collection kits mark the first of many at-home kits that the company plans to roll out in 2021 and reinforces the company's long-term goal of at-home testing and at-home diagnostics to provide better care for Canadians.

"We want to thank Health Canada for the collaborative discussions that resulted in the company's ability to bring this innovative solution to Canada's fight against COVID-19. We look forward to continuing conversations at the provincial level to bring the at-home collection kits to market", says Dilian Stoyanov, Chief Executive Officer of Switch Health.

Switch Health's COVID-19 at-home specimen collection kits provide a Canadian made, all-in-one solution for those requiring asymptomatic testing and will be available as soon as provinces provide approval. The release of Switch Health's proprietary software, ASMO, in conjunction with at-home kits mark two significant milestones for the fast-growing healthcare company who continues to drive forward local innovation in the fight against COVID-19 and beyond.

Rapid Growth in FY 2020
Switch Health's exponential growth in FY 2020 can be attributed to the company's rapid response to creating pandemic solutions. The company now employs over 120 Canadians nationwide and expects that number to double in the next 6 months. Switch Health's local and global top-tier partnerships have contributed to the company's expansion.

While Switch Health continues to find solutions for the fight against COVID-19, the company is focusing on future research and development in artificial antibodies and preventative medicine through AI-powered at-home diagnostic hardware and software.

About Switch Health
Switch Health is a Toronto-based healthcare company dedicated to providing better care at-home for Canadians. Switch Health has quickly become an industry leader in COVID-19 testing solutions and will be rolling out additional at-home testing and at-home diagnostic hardware and software services in 2021. Switch Health currently offers mobile rapid testing and in-clinic testing services to clients across Ontario, Alberta, Nova Scotia and New Brunswick. Switch Health's travel offering provides reliable PCR testing with fast results for eight major airline partners and their passengers. 

For more details on Switch Health, please visit www.switchhealth.ca

At-home specimen collection kits will be available soon in Canada, to join the waitlist please visit https://homekit.switchhealth.ca/. 

SOURCE Switch Health Solutions Inc.

I get all of my shoes from The Shoe Fairy!

I started out simply buying them because I loved their look and style and then they sponsored me.

I never promote or work with brands that I don't truly believe in!

So here are some of my favs!

Use Code: Trainitright at checkout to save an extra 10%

Ontario's doctors' plans for delivering COVID vaccine more urgent in face of record 2,275 daily cases

TORONTO, Dec. 15, 2020 /CNW/ - Ontario's doctors expressed concern that a record 2,275 Ontarians have tested positive for COVID-19 in one day and call on the government to ensure that initial limited supplies of the vaccine are given to those most at risk of being exposed to the virus.

In addition to health-care workers and people who live and work in long-term care homes, the government needs to use real-time data to track geographic areas where the virus is spreading fast and give priority to their residents.

The Ontario Medical Association today released Shining a Light at the End of the Tunnel, a comprehensive set of recommendations to ensure as many people as possible get vaccinated.

Dr. Samantha Hill, president of the Ontario Medical Association, assured Ontarians that the COVID vaccines are safe and that getting vaccinated is one of the most important things they can do to protect themselves and others.

Until a large number of people are vaccinated, it's important to continue to practice good hygiene, including physical distancing, wearing a mask and frequent hand washing, Dr. Hill said.

The new OMA white paper also recommends:

• Administering vaccines in convenient locations — such as hospitals for health-care workers, schools for staff and students and mobile vans for people unable to leave their homes. 
• Moving quickly to book arenas, convention centres and other large indoor and outdoor spaces with cold storage facilities and parking facilities or access to public transportation, as part of government's plans to prepare for possible mass vaccination clinics. 
• Planning should begin now in anticipation of an approved vaccine for children under 16. 
• Undertaking an education campaign to combat vaccine hesitancy and misinformation. 
• Enabling the use of smart phones to make appointments to get the COVID vaccine and receive reminders if they need a booster shot. The smart phone system should align with each type of vaccination, advise primary care physicians when their patents get each dose and provide consent and other information and forms. 
• Developing security precautions to ensure vaccines are not stolen and to shut down criminal behaviour around the falsification or illegal advertising of vaccines, including fake websites, scams and false cures.

"The arrival of the first in what are expected to be a series of different COVID vaccines is an exciting development in what we all hope will be a return to a 'new normal' in 2021," said OMA CEO Allan O'Dette. "Until vaccines are broadly available, we must continue to follow the advice or our public health doctors to protect ourselves and each other. This is how we get our economy back on track." 

About the OMA

The Ontario Medical Association represents Ontario's 43,000-plus physicians, medical students and retired physicians, advocating for and supporting doctors while strengthening the leadership role of doctors in caring for patients. Our vision is to be the trusted voice in transforming Ontario's health-care system.

SOURCE Ontario Medical Association

CSACI Statement on potential adverse reactions to COVID-19 vaccines

OTTAWA, ON, Dec. 15, 2020 /CNW/ - The Canadian Society of Allergy & Clinical Immunology (CSACI) is aware of media reports of two healthcare workers at the National Health Services in the United Kingdom (UK) who experienced adverse reactions on December 8, 2020 after receiving the Pfizer/BioNTech vaccine for COVID-19. This is the same vaccine that was approved for use in Canada on December 9, 2020. Subsequent to the UK reports, Public Health England in the UK made initial broad cautionary recommendations.

The CSACI is the largest national professional medical specialty organization representing Canadian physicians with special expertise in allergy and immunology and who are the preeminent experts in the diagnosis and management of allergic conditions, including vaccine allergy. The CSACI recognizes that the reports from the UK, along with the subsequent general recommendations, will undoubtedly and unfortunately lead to vaccine hesitancy. The CSACI would like to emphasize that the majority of individuals with a history of allergy will be able to safely receive vaccination for COVID-19.

The safety data in the clinical trials for the Pfizer/BioNTech vaccine for COVID-19 did not find a significant number of anaphylaxis events. As with any vaccine, the potential for adverse reactions, including allergic reactions, exists.

The NACI (National Advisory Committee on Immunization) has specifically identified polyethylene glycol (PEG) as a potential allergen in the Pfizer/BioNTech vaccine; however, the CSACI would like to point out that as of this date, PEG has not been confirmed as the cause of reaction for the reported adverse reactions in the UK. PEG is found in multiple products that are tolerated safely on a daily basis by many individuals in Canada, including bowel preparation products for surgical procedures, certain laxatives and other medications, certain skin care products and cosmetics, and some food and drinks. In addition, although allergy to PEG has been reported, it is reassuring to note that no cases of anaphylaxis to PEG in foods and drinks have been reported.

As such, the CSACI would like to commend Health Canada's prudent advice regarding the Pfizer/BioNTech vaccine for COVID-19, stating that ONLY those with known "…allergies to any of the ingredients in the Pfizer-BioNTech COVID 19 vaccine should not receive it…". Health Canada further recommends that individuals "who have experienced a serious allergic reaction to another vaccine, drug or food, …should talk to [their] health professional before [they] receive the vaccine".

The CSACI would like to reassure our fellow Canadians that unless one has a pre-existing allergy to a component of a vaccine, including the Pfizer/BioNTech COVID-19 vaccine, it is safe to proceed with vaccination for COVID-19. In addition, those with other allergic problems are no more likely to experience an allergic reaction to the COVID-19 vaccine than the general population and should safely be able to receive this vaccine—this includes those with a history of serious allergic reactions or anaphylaxis to substances that are not an ingredient in this vaccine, and those with food allergy, eczema, allergic rhinitis (hayfever), asthma, or stinging insect allergy.

We continue to monitor these reports closely and will continue to update our website, www.csaci.ca, as new information arrives.

About the Canadian Society of Allergy and Clinical Immunology (CSACI)

The CSACI is the largest national professional medical specialty organization in Canada representing physicians, allied health professionals and scientists with special expertise in the management of allergic and immunologic diseases. The Society is also dedicated to improving the quality of life of people with allergies through research, advocacy, continuing professional development and public education.

SOURCE Canadian Society of Allergy and Clinical Immunology - CSACI

Loyalist College Ranks #1 For Industry Research Income as Percentage of Total Research Income

BELLEVILLE, ON, Dec. 15, 2020 /CNW/ - Loyalist College reached an institutional milestone today when it was recognized as one of Canada's top 50 research colleges. This is the first time Loyalist has ranked on Research Infosource Inc.'s annual list, placing first in the country for industry research income as a percentage of total research income and eighth for college research income growth.

"What an incredible achievement for Loyalist College, the Bay of Quinte region, and our industry partners," said Dr. Ann Marie Vaughan, Loyalist College President & CEO. "The continued growth and recognition of the College's Applied Research and Innovation Department strengthens our resolve as an institution of choice for small and medium-sized enterprises (SMEs) seeking analytical testing, method optimization, and product development in competitive marketplaces. This achievement reflects our deep commitment to advancing applied research in our region and contributing to a skilled Biosciences workforce to fuel economic growth, entrepreneurialism, and innovation." 

Loyalist's Applied Research Centre for Natural Products and Medical Cannabis houses Canada's only federally supported Technology Access Centre for natural products and cannabis, and is a regional innovation hub for industry to access advanced instrumentation and subject-matter experts.

"Our Applied Research Centre provides student researchers with unprecedented access to work-integrated learning opportunities in a high-tech facility which broadens the range of their scientific aptitude and expands the breadth of their expertise," said Ron Byrne, Loyalist College Senior Vice-President Academic. "We directly connect Bioscience and Cannabis Applied Science students with industry so they can network with future employers and begin their careers." 

The Applied Research Centre offers companies across Eastern Ontario a supportive, community-oriented platform from which to enhance their productivity, expand their reach and augment their competitiveness in the global market. In addition to income from industry partnerships, the Applied Research Centre is funded through the Natural Sciences and Engineering Research Council of Canada (NSERC) College and Community Innovation (CCI) Program, as well as the Canada Foundation for Innovation (CFI), the Ontario Research Fund (ORF), and the Ontario Centres of Excellence (OCE).

To collaborate with Loyalist, one of Canada's top 50 research colleges, please visit loyalistappliedresearch.com.

About Loyalist College
Loyalist is Ontario's Destination College, empowering students, faculty, staff, and partners through experiential, industry cluster-based education, training and applied research programs. The College provides job-ready graduates for, and knowledge transfer to, industry and the community. Of 2017-18 Loyalist graduates, 88.5 percent were employed within six months after graduation. Located on more than 200 acres in the beautiful Bay of Quinte region, the College is perfectly positioned between Toronto, Ottawa and Montreal. Loyalist offers more than 70 full-time diploma, certificate and apprenticeship programs in biosciences, building sciences, business, community service, health and wellness, media studies, public safety, and skilled trades. Continuing education options are available through LoyalistFocus.com, including hundreds of online, distance and in-class courses, and through the College's 100+ university transfer agreements. Loyalist is a key driver of social and economic health in eastern Ontario. It contributes 3.7 percent of the Gross Regional Product, representing $382 million annually to the regional economy – based on a March 2020 report by Emsi. For more information on Loyalist's Belleville, Bancroft and Toronto campuses and Port Hope satellite location, visit YoureGoingPlaces.com.

SOURCE Loyalist College

QEII Foundation announces new chair holder in transplantation research

HALIFAX, NS, Dec. 14, 2020 /CNW/ - The QEII Foundation is pleased to announce Dr. Karthik Tennankore as the new chair holder of the QEII Foundation Endowed Chair in Transplantation Research, for a five-year term. 

This Chair was first established in 2013, thanks to funding from Roche Canada, RBC, and other QEII Foundation donors, and Dr. Tennankore is the second individual to hold this Chair position. 

"As a nephrologist and innovative researcher in the field of nephrology and kidney transplantation, Dr. Tennankore brings a wealth of expertise to this esteemed position," says Susan Mullin, President & CEO of the QEII Foundation. "With ongoing clinical work in kidney transplantation and a nationally-collaborative research network in place, we are confident in Dr. Tennankore's ability to make significant contributions to transplantation research and care in Nova Scotia, through this appointment."

Over the next five years, Dr. Tennankore's research will aim to improve outcomes for organ transplant patients in Nova Scotia, while increasing evidence-informed decision-making among healthcare providers in this critical area of care. Applying extensive expertise in kidney transplantation to a wide variety of organ transplant procedures, his work will focus on three core areas, including:

• developing machine-learning models to identify novel risk factors and combinations of risk factors for patient outcomes after transplantation—in partnership with Dalhousie's Faculty of Computer Science; 
• incorporating measures of a patient's frailty into the transplant decision-making process in Nova Scotia, given new data distinguishing frailty from chronological age; and 
• developing behavioural interventions to increase physical activity in post-transplant patients, for improved recovery and quality of life—in partnership with colleagues in the Department of Medicine. 

"An organ transplant is a gift that can be life-changing"" says Dr. Tennankore. "However, we need better models to understand each patient's unique risks and vulnerabilities, as well as better strategies to provide patients with the tools they need post-transplant, in order to derive the maximum benefit. I look forward to collaborating with experts across the country through my work in this Chair, to improve outcomes for transplant recipients in Nova Scotia and beyond."

Dr. Tennankore is a nephrologist and associate professor at Dalhousie University, in the Department of Medicine at the QEII Health Sciences Centre. He completed an undergraduate degree at Queen's University, a Medical Degree through the University of Western Ontario, and an Internal Medicine residency and Nephrology fellowship through Dalhousie University. He then completed a Master of Science in Clinical Epidemiology from Harvard University. 

About QEII Health Sciences Centre Foundation
The QEII Foundation inspires generosity to advance health care at the QEII. With financial support from all levels of the community, the QEII Foundation helps fund new technologies, medical research, innovation and professional education that contribute to life-changing moments experienced every day by patients and their loved ones. By working together with people who share a vision of better health, the Foundation strengthens care delivered at the QEII, improving the health and lives of Atlantic Canadians.

SOURCE QEII FOUNDATION

BACK SAVING TIPS FOR  PANDEMIC HOLIDAY ROAD TRIPS 

www.nynjspine.com

More than 115 million people took road trips to visit loved ones last holiday season. That was pre-Covid. This year, exponentially more people will be driving long distances in cars to avoid crowded airports and airplanes. There are folks who might be driving cross country or down the northeast coast and spending in excess of 10 hours in a cramped car. Even for those who don’t normally have back pain, this type of situation can cause it. 

Below are some tips from NYC Area Orthopedic and Spinal Surgeon Dr. Gbolahan Okubadejo on avoiding or mitigating back pain while driving this holiday season. 

Get comfortable immediately

Take the time to make sure you're comfortable from the moment you set off on your trip. Discomfort at the beginning of your trip can turn into nagging pain later.

Keep your back pockets empty. 

Sitting on your wallet, phone, or anything else may throw your spine out of alignment.

Mind your posture 

Position your knees slightly higher than your hips, and keep your chin pulled in so that your head sits straight on top of your spine.

Sit a comfortable distance from the steering wheel.

Sit with your breastbone at least 10 inches from the steering wheel, and keeping your hands on the wheel at 9 and 3 (the sides rather than the top of the wheel). But don’t sit too far away either, which can cause you to reach too far for the wheel and places more stress on the lumbar spine, neck, shoulder, and wrists.

Shift in your seat periodically 

When possible, try to move a little in your seat. Even 10 seconds of movement and stretching is preferable than sitting still. At a minimum adjust your seat and change your position slightly every 15 to 20 minutes. Pump your ankles to keep the blood flowing and provide a slight stretch in your hamstring muscles. Any movement that is safe to do in the car will help you alleviate back strain. 

Make your ride as smooth as possible

Bumps in the road can jar your spine and increase pain. For a smoother ride, consider:

Aim for a Smooth Ride 

Replacing worn shocks to limit the bounce in the car

Replacing worn tires to reduce vibration or shaking

Sit on a car seat pillow or coccyx cushion to provide more padding between you and the road.

Move yourself

Sitting in one position in a car will stiffen up your back muscles and can lead to achiness and possibly muscle spasms. Everyone should ideally take at least a 15-minute break for every 2 hours of driving. If you’re prone to back pain, you may want to take breaks more frequently, such as every 30 to 60 minutes.

What to do if you’re in pain 

Cold therapy can help reduce inflammation and swelling. Consider bringing a cooler to store reusable ice packs or other cold therapy packs. 

Heat therapy can help increase blood flow and relax the muscles. Various types of heat therapy are available to buy, such as heat wraps or heat pads.

Note about application: It is recommended to apply ice or heat for only 15 or 20 minutes at a time, then give your skin a rest to recover for at least a couple hours before the next application.

About the Doctor

Gbolahan Okubadejo, MD, FAAOS, leads The Institute for Comprehensive Spine Care, with offices in the greater New York City area, as a spinal and orthopedic surgeon. Board-certified and fellowship-trained, Dr. Okubadejo specializes in the treatment of degenerative spinal disease, spinal deformity, and cervical, lumbar, and thoracic conditions.

Dr. Okubadejo earned his undergraduate degree at Brown University in Providence, Rhode Island, and his medical degree at Johns Hopkins University School of Medicine in Baltimore. He completed his internship and orthopedic surgery residency at Barnes-Jewish Hospital at the Washington University School of Medicine in St. Louis. Dr. Okubadejo completed a spinal surgery fellowship at the University of Pittsburgh Medical Center in Pittsburgh.

Dr. Okubadejo is a published research author and has presented his findings at several major spinal conferences around the globe. While a surgical resident, he won the Leonard Marmor Surgical Arthritis Foundation Resident Award for the best research project.

In 2017, Dr. Okubadejo formed company 360 Dynamized Core, which is focused on creating innovative, spine safe core fitness products and routines. The first patented product, 360

CoreBoard, launched to the market in 2020. Find out more at 360coreboard.com

Dr. Okubadejo believes in the power of preventive care, minimally invasive surgical procedures, open communication with patients, and personalized care. When he’s not caring for patients, he enjoys traveling, learning about different cultures and the arts, and playing golf.